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Phirty-Day Incidence and Six-Month Clinical
utcome of Thrombotic Stent Occlusion After
are-Metal, Sirolimus, or Paclitaxel Stent Implantation
ndrew T. L. Ong, MBBS, FRACP, Angela Hoye, MBCHB, MRCP, Jiro Aoki, MD,
arlos A. G. van Mieghem, MD, Gaston A. Rodriguez Granillo, MD, Karel Sonnenschein,
velyn Regar, MD, PHD, Eugene P. McFadden, MBCHB, MD, FRCPI, FACC,
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otterdam, The Netherlands
OBJECTIVES We sought to determine the real-world incidence of angiographically confirmed and possible
stent thrombosis (ST) in an unrestricted population during the first 30 days after bare-metal
stent (BMS), sirolimus-eluting stent (SES), and paclitaxel-eluting stent (PES) implantation.
BACKGROUND Current data on ST in drug-eluting stents (DES) have come from randomized trials with
strict entry criteria, which limits their generalizability to daily practice.
METHODS The study population comprised three sequential cohorts of 506 consecutive patients with
BMS, 1,017 consecutive patients with SES, and 989 consecutive patients treated with PES.
RESULTS In the first 30 days after stent implantation, 6 BMS (1.2%, 95% confidence interval [CI] 0.5%
to 2.6%; p  0.9), 10 SES (1.0%, 95% CI 0.5% to 1.8%), and 10 PES (1.0%, 95% CI 0.6%
to 1.9%) patients developed angiographically proven ST. Multiple potential risk factors were
identified in most patients with ST. Bifurcation stenting in the setting of acute myocardial
infarction was an independent risk factor for angiographic ST in the entire population (odds
ratio [OR] 12.9, 95% CI 4.7 to 35.8, p 0.001). In patients with DES who had angiographic
ST, 30-day mortality was 15%, whereas another 60% suffered a nonfatal myocardial
infarction; no further deaths occurred during six months of follow-up. Including possible
cases, 7 BMS (1.4%, 95% CI 0.7% to 2.8%), 15 SES (1.5%, 95% CI 0.9% to 2.4%), and 16
PES (1.6%, 95% CI 1.0% to 2.6%) patients had ST.
CONCLUSIONS The unrestricted use of SES or PES is associated with ST rates in the range expected for
BMS. Stent thrombosis was associated with a high morbidity and mortality. Bifurcation
stenting, when performed in patients with acute myocardial infarction, was associated with an
increased risk of ST. (J Am Coll Cardiol 2005;45:947–53) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.079College of Cardiology Foundation
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crug-eluting stents (DES) reduce clinical events related to
estenosis. Concerns have been raised regarding the inci-
ence of stent thrombosis (ST) with the unrestricted use of
hese stents. Data from the bare-metal stent (BMS) era
eport a high morbidity and mortality with ST (1,2).
vidence for ST in DES has come from randomized
ontrolled trials with strict entry criteria for the treatment of
ingle lesions, limiting conclusions that are applicable to the
eal-world setting (3–6). Other information has come from
lectronic registries with inherent biases that preclude gen-
ralization of the findings. A single-center registry recently
eported its results with sirolimus-eluting stents (SES) (7).
he aim of this present study is to describe the incidence of
T (both angiographically proven and including possible
ases) in three consecutive populations while analyzing the
nrestricted use of a control BMS group, SES, and
aclitaxel-eluting stents (PES).
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tudy design and patient population. Since April 2002,
ES (Cypher; Cordis Corp., Miami Lakes, Florida, a
ohnson & Johnson Company) have been the stents of
hoice for all percutaneous coronary interventions irrespec-
ive of their clinical presentation or clinical outcome (8). In
he first quarter of 2003, PES (Taxus; Boston Scientific
orp., Natick, Massachusetts) replaced SES as the default
tent.
This present study comprises three sequential cohorts: a
ontrol group of the last 506 consecutive patients treated
ith BMS before April 2002; 1,017 consecutive patients
ith SES treated between April 2002 and February 2003;
nd 989 consecutive patients with PES treated between
ebruary 2003 and December 2003.
rocedure and antiplatelet management. All interven-
ions were performed according to current standard guide-
ines, and the final interventional strategy including peripro-
edural glycoprotein IIb/IIIa and intravascular ultrasound
se, was left to the discretion of the operator. Patients were
retreated with aspirin and a loading dose of 300 mg of
lopidogrel. After their procedure, all patients were pre-
cribed a lifelong aspirin regimen. Clopidogrel was pre-
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Stent Thrombosis in Drug-Eluting Stents March 15, 2005:947–53cribed for at least one month in the BMS group, for at least
hree months in the SES group (8), and for at least six
onths in the PES group.
ollow-up. As part of the national health system, our
nstitution as a tertiary referral center is the only interven-
ional facility within our catchment area. The survival status
f our patients at one and six months after discharge was
btained from the Municipal Civil Registries. Details of all
epeat interventions (surgical and percutaneous) were col-
ected prospectively during follow-up. Referring physicians
nd institutions were contacted whenever necessary for
dditional information. This protocol was approved by the
ospital Ethics Committee, and written, informed consent
as obtained from every patient.
Table 1. Baseline and Procedural Characteristi
B
(n
Baseline characteristics
Age, yrs, mean  SD 61.0
Male, %
Diabetes, %
Hypercholesterolemia, %
Current smoker, %
Hypertension, %
Previous MI, %
Previous PCI, %
Previous CABG, %
Multivessel disease, %
Indication for index procedure
Stable angina, %
Unstable angina, %
Acute MI, %
Silent ischemia, %
Number of vessels treated, mean  SD 1.4
LAD, n
LCx, n
RCA, n
Others, n
Total stent length, mm (mean  SD) 31.9
Stents implanted, mm (mean  SD) 1.9
At least one 2.5 mm stent implanted (%)
Bifurcations stented, %
Glycoprotein IIb/IIIa use (%)
BMS  bare metal stent; CABG  coronary artery bypass
Abbreviations and Acronyms
AMI  acute myocardial infarction
BMS  bare-metal stents
CI  confidence interval
DES  drug-eluting stents
MI  myocardial infarction
OR  odds ratio
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
ST  stent thrombosis
TIMI Thrombolysis In Myocardial InfarctionMI myocardial infarction; PCI percutaneous coronary interven
artery; SES  sirolimus-eluting stent.efinitions. Stent thrombosis was considered to have oc-
urred when confirmed angiographically: either Thrombol-
sis In Myocardial Infarction (TIMI) flow grade 0 or 1 or
he presence of flow-limiting thrombus (TIMI flow grade 1
r 2) occurring in an acute (within 24 h of stent implanta-
ion) or subacute (between 1 and 30 days) time period after
tent implantation (9). In addition, a clinical definition of
possible stent thrombosis” was used for patients who
ithin the first 30 days experienced sudden death, who
uffered a fatal out-of-hospital cardiac arrest, or who suf-
ered a myocardial infarction (MI) that was not clearly
ttributable to another coronary lesion and who did not
ndergo repeat angiography. All deaths and MIs were
eviewed independently by two interventional cardiologists
A.O., E.Mc.F) for “possible stent thrombosis.”
tatistical analysis. Categorical variables were compared
sing the Fisher exact test and continuous variables with the
tudent t test or one-way analysis of variance where appro-
riate. Univariate and forward stepwise (entry criteria of
.05 and exit criteria of 0.10) multivariate logistic regression
nalysis were performed to identify characteristics or vari-
bles independently associated with stent thrombosis. From
he univariate analysis, the following baseline, clinical,
ngiographic and procedural variables were entered into the
ultivariate model: bifurcation stenting, diabetes, smallest
tent diameter, multilesion stenting, and acute myocardial
nfarction (AMI) as the indication. All probability values are
6)
SES
(n  1,017)
PES
(n  989) p Value
.4 61.9  11.3 61.7  11.4 0.3
70 74 0.1
18 17 0.6
55 60 0.01
28 28 0.01
41 41 0.9
32 35 0.01
25 26 0.2
9 8 0.2
57 56 0.4
0.01
43 41
36 30
19 26
2 3
6 1.4  0.6 1.4  0.6 0.8
594 540
332 333
398 384
75 90
.1 42.5  29.6 44.2  29.4 0.01
1 2.3  1.5 2.2  1.4 0.01
38 38 0.01
18 17 0.01
21 28 0.01
g; LAD  left anterior descending; LCx  left circumflex;cs
MS
 50
 11
73
16
52
35
40
43
22
11
54
42
35
20
3
 0.
281
164
194
29
 22
 1.
23
5
37
graftin
tion; PES paclitaxel-eluting stent; RCA right coronary
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March 15, 2005:947–53 Stent Thrombosis in Drug-Eluting Stentswo-sided, and statistical significance was set at the 0.05
evel. A cumulative event graph consisting of patients with
ngiographic stent thrombosis was generated plotting the
roportion of patients with stent thrombosis (Y-axis)
gainst time (X-axis) stratified by stent type. Incidences of
tent thrombosis are reported as a percentage with associ-
ted 95% confidence intervals (CIs).
ESULTS
aseline and procedural characteristics. The patients in
ur cohort were at high risk, with unstable angina or AMI
eing the indication in more than one-half of the cases
Table 1). Multivessel disease was present in more than
ne-half of the population. One-third of the population had
previous AMI, whereas one-quarter had previous coronary
nterventions. Glycoprotein IIb/IIIa use was lower in the
ES and PES groups compared with the BMS group.
linical outcome. Angiographic ST was documented in
6 of 2,512 patients (Table 2). Six cases occurred in the
MS group (1.2%, 95% CI 0.5% to 2.6%), 10 cases
ccurred in the SES group (1.0%, 95% CI 0.5% to 1.8%),
nd 10 cases occurred in the PES group (1.0%, 95% CI
.6% to 1.9%). The first two SES patients with ST have
een reported previously (10). Most stent thromboses oc-
igure 1. Cumulative incidence of angiographic stent thrombosis stratified
y groups against time. Vertical line  day 11 on horizontal axis. BMS 
Table 2. Outcome Following Angiographic St
BMS
Angiographic stent thrombosis, n (%) 6 (1.2%
Clinical presentation
Acute MI, n 5
Angina, n 1
Maximum total CK, mean  SD 4,983 
Maximum CK-MB, mean  SD 397 
Outcome
30-day mortality, n 0
6-month mortality, n 0
CK  creatine kinase; other abbreviations as in Table 1.d
are-metal stents; PES  paclitaxel-eluting stents; SES  sirolimus-
luting stents.urred in the first 11 days, regardless of stent type, with a
ean time to event of 5.8  5.4 days (Fig. 1).
In the BMS population, there were two acute stent
hromboses and four subacute stent thromboses. Among the
ix patients, ST presented as AMI in five patients. None
ied during the six months of follow-up (Table 2). In the
ombined group of SES and PES (2,006 patients), there
ere 2 cases of acute ST and 18 cases of subacute ST (Fig.
). A detailed description of these patients is given in Table
. Analysis via intravascular ultrasonography was performed
n four patients. In most patients, at least one recognized
isk factor for ST (i.e., long stented length, use of small
tents, use of multiple stents, and residual dissection after
tent implantation) was present. Importantly, 2 of the 20
atients had not taken clopidogrel.
ortality and morbidity. Overall, 20 of 26 patients (77%)
e-presented with an AMI, whereas the other 6 re-
resented with angina pectoris (Table 2). Of these 26
atients, 3 (Patients #12, #18, and #20 from Table 3—all in
he DES population) died at days 11, 5, and 3, respectively.
wo patients died during reintervention from intractable
entricular fibrillation, whereas the third underwent emer-
ency surgery after a suboptimal reintervention and could
ot be weaned from bypass. The incidence of death at 30
ays was 12%, whereas another 65% suffered a nonfatal MI.
mong the survivors of ST, there were no further deaths in
he six months after reintervention.
ossible ST. Thirty-day survival data was complete for
8% of patients (Table 4). There were 12 patients who were
udged with “possible stent thrombosis,” of which 9 died
nd 3 had nonfatal MIs. Of the nine deaths, four were
ut-of-hospital sudden deaths, three occurred in hospital
ith ventricular tachycardia as the initiating preterminal
hythm, and two had ST-segment elevation and died before
hey could undergo reangiography. Among those with MIs,
ne patient developed a postprocedural enzyme leak, and
nother developed ventricular fibrillation requiring multiple
ardioversions the day after the procedure. Repeat coronary
ngiography six months later demonstrated occluded stents
n both of these patients; whereas a third underwent
oronary angiography 14 days after stent implantation
ecause of an increase in cardiac enzyme levels, which
hrombosis
SES PES p Value
10 (1.0%) 10 (1.0%) 0.9
7 8
3 2
1,268  476 3,361  1,404 0.01
171  80 322  166 0.01
0 3
0 3ent T
)
2,570
186emonstrated an in-stent filling defect which was treated
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aneous coronary intervention two weeks later. Including
he suspected cases, the combined incidence of angiographic
nd possible ST was 1.4% (95% CI 0.7% to 2.8%) in the
MS control group, 1.5% (95% CI 0.9% to 2.4%) in the
ES group, and 1.6% (95% CI 1.0% to 2.6%) in the PES
roup. In the combined total of 38 documented and possible
T, there were 12 deaths (32%) and 20 nonfatal MIs (53%)
n the first 30 days.
ultivariate analysis. By univariate analysis, bifurcation
tenting was the only significant factor (p  0.01). Multi-
ariate analysis was performed with the following covariates
ased on their significance on univariate analysis as well as
heir potential clinical impact: diabetes (p  0.07), smallest
tent diameter (p  0.13), multilesion stenting (p  0.17),
able 3. Detailed Description of Drug-Eluting Stent Patients W
atient 1 2 3 4
ype of DES SES SES SES SES
ime to Thrombosis (days) 0.125 11 7 10
aseline characteristics
Age (yrs) 72 61 86 57
Gender F F F M
Diabetes    
Current smoker    
Previous MI    
Previous intervention    
ndex procedure
Indication for procedure UAP AP UAP AMI, ST
Glycoprotein IIb/IIIa use    Y
ngiographic features of index procedure
Culprit vessel LAD LAD LAD LAD
Lesion type (AHA) B1 C C C
Bifurcation technique (where
performed)
   
Final kissing balloons in bifurcation
stenting
   
Minimum stent diameter (mm) 2.25 2.5 3 3
Total stent length (mm) 26 66 41 26
Total stents implanted 2 2 3 2
eintervention
Clinical presentation AMI AP AMI AP
Additional stent implanted Y  Y Y
IVUS findings (where performed) RD UD  RD
Site of thrombosis in bifurcation lesions    
Incomplete oral anti-platelet therapy    
Successful procedural outcome Y Y Y Y
MI acute myocardial infarction; AP angina pectoris; DIAG diagonal branch
rtery; MB  mainbranch; N  no; OMCx  obtuse marginal branch; RCA  right
unstable angina pectoris; UD  underdeployment; Y  yes; other abbreviations a
able 4. Incidence of Stent Thrombosis Classified by Definition
Stent Type
Number of
Patients
Angiographically Pr
Stent Thrombos
n (% [95% CI]
BMS 506 6
(1.2% [0.5%–2.6%
SES 1,017 10
(1.0% [0.5%–1.8%
PES 989 10
(1.0% [0.6%–1.9%I  confidence interval; other abbreviations as in Table 1.MI as the indication (p  0.3), and bifurcation stenting.
y multivariate analysis, bifurcation stenting was the only
ndependent predictor of ST (odds ratio [OR] 3.0, 95% CI
.3 to 6.8, p  0.01). When the interaction of bifurcation
tenting by AMI was entered as a covariate, it was highly
ignificant (OR 12.9, 95% CI 4.7 to 35.8, p  0.001), and
ifurcation stenting as a covariate was no longer significant.
ISCUSSION
he main findings in this study can be summarized as
ollows: 1) the incidence of angiographic ST in an un-
elected, complex DES population was low (1.0%), within
he same range as the corresponding BMS population and
oncordant with previously published results from the BMS
ngiographic Stent Thrombosis
5 6 7 8 9 10
SES SES SES SES SES SES
1.08 6 3 7 17 3
75 55 53 58 58 74
F F M M M M
     
     
     
     
AP AP, ISR UAP post-AMI AP AMI UAP post-AMI
   Y Y 
/DIAG LAD/DIAG RCA LAD DIAG LAD
B2 C B2 B2 B2 B2
crush t-stent   t-stent 
Y N N
3 2.5 3 2.75 3 2.75
36 41 41 18 31 36
2 2 2 1 2 2
AMI AMI AMI AP AMI AMI
  Y  
    UD
BSB SB   SB 
    Y 
Y Y Y Y Y Y
intermediate branch; LAD left anterior descending artery; LCx left circumflex
ary artery; RD  residual dissection; SB  sidebranch; ST  stent thrombosis; UAP
able 1.
Possible Stent
Thrombosis
n (% [95% CI])
All Stent Thrombosis
n (% [95% CI])
1 7
(0.2% [0.0%–1.1%]) (1.4% [0.7%–2.8%])
5 15
(0.5% [0.2%–1.1%]) (1.5% [0.9%–2.4%])
6 16
(0.6% [0.3%–1.3%]) (1.6% [1.0%–2.6%])ith A
LAD
M
; IMoven
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ncidence of ST to 1.5%; 3) angiographically proven ST
as associated with a high mortality and morbidity; 4)
atients who developed ST often had multiple high-risk
eatures, regardless of stent type; and 5) the association of
ifurcation stenting for AMI was a highly significant
ndependent risk factor for ST.
The availability of DES as the default stent at our
nstitution has allowed us to analyze this new technology in
n unrestricted population (8), a population that would
ave comprised any BMS population in the pre-DES
ra. Therefore, this availability allows us to analyze inci-
ences in an “all-comers” population because patients were
nrolled irrespective of clinical presentation or outcome. In
able 3 Continued
11 12 13 14 15 16
PES PES PES PES PES PES
0.04 4 7 6 3 4
59 50 67 47 61 52
M M M F M F
     
     
     
     
AMI AMI AP AMI AP AMI
   Y  
RCA LAD OMCX LAD/DIAG LCx LCx/OMCx
B2 B2 C C B2 C
  crush crush  t-stent
  N N  N
3 3.5 2.5 2.5 2.5 2.25
28 24 32 36 20 44
1 1 2 2 1 2
AMI AMI AMI AMI AMI UAP
  Y  Y 
     
  SB SB  SB
    Y 
Y Died Y Y Y Y
Table 5. Clinical Trials on Drug-Eluting Sten
Trial Name
Number of Patients
in Drug-Eluting Arm
SIRIUS (3) 533
E-SIRIUS (6) 157
C-SIRIUS (5) 50
TAXUS-IV (4) 662
SES group 1,017
PES group 989
*Definition of stent thrombosis was not stated. †Stent thr
myocardial infarction in the first 30 days. ‡Stent thrombosis
angiographically proven, or adjudicated death or myocardial infarc
Abbreviations as in Table 1.his population sample, angiographic ST rates in the first 30
ays for both DES, i.e., SES and PES, occurred within the
ange as that reported in the BMS era (1,2,11,12).
The angiographic definition used is the most accurate for
iagnosis but may underestimate the true incidence of ST
ecause some patients who have a presumed ST may die
efore receiving medical attention. Conversely, the use of
ajor adverse cardiac events (i.e., death and MI in addition
o the angiographic findings) to define ST overestimates the
rue incidence because not all patients who die suddenly or
uffer a MI do so because of ST (13). This consideration is
mportant in our heterogeneous unrestricted population
ith multivessel disease, previous MI, and previous revas-
ularization. Furthermore, not all patients who die will
17 18 19 20 Mean  SD, %
PES PES PES PES
24 5 5 3 6.3  5.7
0 54 65 31 59.7  11.9
M M M M 13 M:7 F
    30%
    30%
    45%
    25%
AP AMI AP AP
 Y Y  30%
LCx LAD/Diag LAD/IM/LCx LAD
C C C B2
 crush culotte crush  40%
 N Y 
2.25 2.75 2.25 3 2.7  0.3
2 36 140 84 41.2  27.8
2 2 8 4 2.2  1.5
UAP AMI AMI AMI AMI  75%
Y    Yes  35%
   
BSB SB MBSB 
    10%
Y Y Died Died Death  15%
Total Stent
Length mm
(Mean  SD)
Incidence of Stent
Thrombosis in the
First 30 Days (%)
23.0  8.6 0.2*
21.5  6.7 1.1*
23.8  8.4 2.0*
21.9  8.1 0.3†
42.5  29.6 ‡1.0–1.5§
44.2  29.4 ‡1.0–1.6§
is defined as angiographically proven, or cardiac death or
d as angiographically proven. §Stent thrombosis defined as6
3
Mts
ombos
definetion in the first 30 days.
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Stent Thrombosis in Drug-Eluting Stents March 15, 2005:947–53ndergo autopsy studies to determine the cause of death. To
ttenuate this overestimation and to provide an accurate
gure, we have adjudicated all deaths and noncatheterized,
onfatal MIs within the first 30 days in the three groups and
ncluded them with the angiographically proven patients to
rovide an overall incidence for each group.
The incidences of ST for both groups of DES are within
he range reported in the larger randomized clinical trials of
ES (3–6) despite longer total stent length, multivessel
reatment, and a heterogeneous population (Table 5). This
ncidence complements information already available from
he randomized trials regarding the safety of these new
evices.
Angiographic ST was associated with a high mortality
nd morbidity in our study. Within the DES population, 15
atients (75%) experienced a MI as their diagnosis at the
econd presentation, and 3 (15%) died during the reinter-
ention procedure. The inclusion of possible ST patients
ncreased the mortality to 32%. Given the small number of
vents, the fact that no deaths occurred in the BMS group
as most likely due to chance. These results are in concor-
ance with the results of a large BMS registry (2).
Previous studies have demonstrated that residual dissec-
ion (1,11), long stents (1), small final lumen diameter (1),
nd use of multiple stents (2) are risk factors for the
evelopment of ST. In our series, multiple risk factors were
dentified in most patients who developed ST. Patients with
T had more multiple lesions treated, smaller minimum
tent diameters, and longer stent lengths compared with
hose without ST; however, these factors were not signifi-
ant on univariate analysis. What did emerge and which has
ot been previously reported is that patients undergoing
ifurcation stenting had a higher incidence of ST compared
ith those without bifurcation stenting. A recent study on
ifurcations reported a 3.5% incidence of ST, which is
igher than the overall incidence in this population (14).
Although stent implantation for AMI was not significant
n univariate analysis, the interaction of AMI and bifurca-
ion stenting when entered as a covariate for ST on
ultivariate analysis emerged as a highly significant inde-
endent predictor, and bifurcation stenting as a covariate
as no longer significant. This result confirms a clinical
uspicion in our department regarding the increased risk of
T in patients treated with bifurcation stenting in the
etting of AMI.
Mechanical reasons that predispose to ST can be modi-
ed by interventional technique. Optimizing stent place-
ent including, if necessary, intravascular ultrasound-
uided postdilation, kissing balloon postdilation with
ifurcation stenting, and careful inspection for residual
issection after stent implantation, may further reduce the
ncidence of ST.
Pharmacologic reasons for ST, i.e., inadequate antiplate-
et therapy, are patient-specific factors. Recent research
iterature has focused on “resistance” to either aspirin (15) or
o clopidogrel (16). Currently, most laboratories do not Coutinely test for antiplatelet resistance. In our series, two
atients who had not taken their prescribed clopidogrel after
he procedure developed ST.
This report covers ST occurring in the first 30 days after
tent implantation only, during which all patients received
ual antiplatelet therapy. The duration of clopidogrel ther-
py differed among the three groups; in part, it reflects
ncertainty with regards to re-endothelialization after DES
mplantation. Late ST has been reported to occur with
MS (17) and with DES (18), including a reported fatality
19) after clopidogrel discontinuation. At this stage, the
ncidence of late ST in the DES era is unknown, and further
tudies are required to clarify this potential late complica-
ion.
omment on sample size and statistical comparisons.
ecause ST occurs at a low incidence (1.0 to 1.5%), a
mall sample size may underestimate or overestimate the
rue incidence. In a previously published report from our
nstitution, we reported an angiographic incidence of 0.4%
n 508 patients (8). In the present study we extended the
opulation to incorporate the entire period of DES used to
ate at our institution (n  2,006) to allow a more accurate
nalysis of the true incidence of ST in the DES population.
espite having 2,512 patients, the low and small/negligible
bsolute difference in incidence precludes formal statistical
omparisons of ST rates among the three groups because it
acks sufficient statistical power. To achieve adequate power
ould require sample sizes in the order of 100,000
atients. To date, this study is the largest series of patients
eported on in the DES era.
tudy limitations. These single-center registry data com-
lement available randomized data, as they reflect the results
f unrestricted DES use.
onclusions. Despite having a more complex cohort with
igh-risk inclusion criteria, longer stent lengths, and more
omplex procedural features, the incidence of ST with DES
re in the same range as the BMS population observed in
ur present study. They also are in agreement with previ-
usly reported data by others from the BMS era and with
hose results reported on in the earlier randomized DES
rials. Furthermore, the two groups of DES, i.e., SES and
ES, share an incidence of 1.0% to 1.5%. Stent throm-
osis is associated with a high morbidity and mortality.
As extensively documented in previous reports with BMS,
echanical reasons were observed to be frequent associations
or ST with DES. In this study, bifurcation stenting in the
etting of AMI was a highly significant independent predictor
or angiographic ST.
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